Boehringer dumps its $250M NASH drug; Bavarian Nordic sells PRV for $95M; GBT inks deal with Syros, gets $150M loan
→ Four years after Boehringer handed out a $250 million deal to get a NASH drug from Pharmaxis, they’re sweeping it out of the pipeline. The German pharma company noted today that the drug posed a threat of drug interactions, scuttling its aspirations for the program. BI 1467335 joins a long — and growing — list of failures in the NASH field, where drug developers have been trying to field a therapy that can bend the needle on a disease that afflicts millions of people worldwide.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.